Get the latest news, insights, and market updates on PTCT (PTC Therapeutics, Inc.). Explore the news page 6 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy. On October 20, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on PTC Therapeutics, Inc. (NASDAQ:PTCT), lifting the price target on the stock to $87 from $76. The analyst cited the solid initial demand for Sephience, which is […] Oct 28, 2025 - $PTCT
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2025, the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 1,990 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. Oct 27, 2025 - $PTCT
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic communications, and equity capital markets across the life sciences sector Oct 9, 2025 - $PTCT
PTC Therapeutics (PTCT): Assessing Valuation After New Huntington’s Data Shifts Competitive Landscape and Investor Sentiment
If you’re holding or eyeing shares in PTC Therapeutics (PTCT), recent news probably has your full attention. uniQure’s Phase 1/2 gene therapy results for Huntington’s disease made waves by showing a 75% reduction in disease progression. This has sparked immediate questions about how PTC’s votoplam program might compare to such competition. With the spotlight shifting away from PTC’s own development and insider selling coming to light, investors are analyzing what these events mean for future... Sep 29, 2025 - $PTCT
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. PTC Therapeutics, Inc. is one of them. PTC Therapeutics, Inc. (NASDAQ:PTCT) is reinforcing its position in rare disease innovation with the launch of SUFIANCE (sepiapterin) for phenylketonuria (PKU). Recently approved by both the FDA and EU, […] Sep 11, 2025 - $PTCT
RareMed Announces Expansion of Relationship with PTC Therapeutics
RareMed Solutions®, the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics™ with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience™. The recent approval of Sephience by the FDA marks a significant milestone in the treatment of phenylketonuria (PKU) for both adult and pediatric patients. This new therapy, developed by PTC, has the potential to transform the lives of tho Sep 2, 2025 - $PTCT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple